» Articles » PMID: 17709410

In Vitro and in Vivo Characterization of Anthrax Anti-protective Antigen and Anti-lethal Factor Monoclonal Antibodies After Passive Transfer in a Mouse Lethal Toxin Challenge Model to Define Correlates of Immunity

Overview
Journal Infect Immun
Date 2007 Aug 22
PMID 17709410
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Passive transfer of antibody may be useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bacillus anthracis. Studies were performed to evaluate the ability of anthrax antiprotective antigen (anti-PA) and antilethal factor (anti-LF) neutralizing monoclonal antibodies (mAbs) to protect against an anthrax lethal toxin (LeTx) challenge in a mouse model and to identify correlates of immunity to LeTx challenge. Despite having similar affinities for their respective antigens, anti-PA (3F11) and anti-LF (9A11), passive transfer of up to 1.5 mg of anti-PA 3F11 mAb did not provide significant protection when transferred to mice 24 h before LeTx challenge, while passive transfer of as low as 0.375 mg of anti-LF 9A11 did provide significant protection. Serum collected 24 h after passive transfer had LeTx-neutralizing activity when tested using a standard LeTx neutralization assay, but neutralization titers measured using this assay did not correlate with protection against LeTx challenge. However, measurement of LeTx-neutralizing serum responses with an LeTx neutralization assay in vitro employing the addition of LeTx to J774A.1 cells 15 min before the addition of the serum did result in neutralization titers that correlated with protection against LeTx challenge. Our results demonstrate that only the LeTx neutralization titers measured utilizing the addition of LeTx to J774A.1 cells 15 min before the addition of sample correlated with protection in vivo. Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies.

Citing Articles

Characterization of the UK anthrax vaccine and human immunogenicity.

Modi T, Gervais D, Smith S, Miller J, Subramaniam S, Thalassinos K Hum Vaccin Immunother. 2020; 17(3):747-758.

PMID: 32897798 PMC: 7993152. DOI: 10.1080/21645515.2020.1799668.


Functional characterization and evaluation of protective efficacy of EA752-862 monoclonal antibody against B. anthracis vegetative cell and spores.

Majumder S, Das S, Kingston J, Shivakiran M, Batra H, Somani V Med Microbiol Immunol. 2019; 209(2):125-137.

PMID: 31811379 DOI: 10.1007/s00430-019-00650-5.


Amino acid starvation enhances vaccine efficacy by augmenting neutralizing antibody production.

Afroz S, Shama , Battu S, Matin S, Solouki S, Elmore J Sci Signal. 2019; 12(607).

PMID: 31719173 PMC: 7271814. DOI: 10.1126/scisignal.aav4717.


Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Sterne strain.

Caldwell M, Hathcock T, Brock K PeerJ. 2017; 5:e3907.

PMID: 29259839 PMC: 5733894. DOI: 10.7717/peerj.3907.


A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax.

Xiong S, Tang Q, Liang X, Zhou T, Yang J, Liu P Sci Rep. 2015; 5:11776.

PMID: 26134518 PMC: 4488766. DOI: 10.1038/srep11776.


References
1.
Hall E, Wierzba T, Ahren C, Rao M, Bassily S, Francis W . Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immun. 2001; 69(5):2853-7. PMC: 98234. DOI: 10.1128/IAI.69.5.2853-2857.2001. View

2.
Pittman P, Mangiafico J, Rossi C, Cannon T, Gibbs P, Parker G . Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine. 2000; 19(2-3):213-6. DOI: 10.1016/s0264-410x(00)00174-2. View

3.
Fellows P, Linscott M, Ivins B, Pitt M, Rossi C, Gibbs P . Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine. 2001; 19(23-24):3241-7. DOI: 10.1016/s0264-410x(01)00021-4. View

4.
Price B, Liner A, Park S, Leppla S, Mateczun A, Galloway D . Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun. 2001; 69(7):4509-15. PMC: 98526. DOI: 10.1128/IAI.69.7.4509-4515.2001. View

5.
Xu W, Li P, Wood C, He J, Du Q, Bhat G . Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol. 2001; 4(2):55-61. View